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Abstract
N-Acetylglucosamine (O-GlcNAc) modification on serine or threonine residues of cytoplasmic and nuclear proteins has
become a more recognized intracellular covalent modification. Removal of this modification is carried out by N-acetyl-
L-glucosaminidase (O-GlcNAcase). Since little information exists on monoglycosylation and O-GlcNAcase activity in
mitogenic systems, we investigated O-GlcNAcase activity in primary breast tumors compared to matched normal adjacent
breast tissue and examined enzymatic activity in relationship to the level of protein monoglycosylation. Using a variation of
the acidic hexosaminidase activity assay, we demonstrated an increase in both O-GlcNAcase and lysosomal hexosaminidase
activity in breast tumor tissue compared to matched adjacent tissue. Although no clear correlation with tumor grade or type
was apparent among the samples examined (12 matched pairs), the increase in O-GlcNAcase and lysosomal hexosaminidase
activity in tumor tissue was consistently elevated and statistically significant (P6 0.05). Protein monoglycosylation was
evaluated using immunoblotting, affinity blotting, and radioactive labeling. While the variety of modified proteins was
greater in tumor tissue compared to adjacent tissue, the total amount of O-GlcNAc monoglycosylation was significantly
decreased in the tumor tissue especially on proteins in the molecular mass range of 45^65 kDa. O-GlcNAcase may be
involved in the selective removal of O-GlcNAc on certain proteins in breast tumor tissue. ß 2001 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Mitogenic stimulation activates one or more
protein phosphorylation/dephosphorylation cascades
directly activating speci¢c enzyme pathways and
modi¢es transcription factor binding to DNA [1,2].
Uncontrolled cell proliferation is often the result of
the cell’s inability to control signaling cascades due
to aberrant phosphorylation. The control of phos-
phorylation is performed by kinases and phospha-
tases that add or for the latter remove a phosphate
residue. Another recently discovered protein modi¢-
cation that may in£uence the function of proteins is
the addition of a single N-acetylglucosamine moiety
to a serine or threonine (O-GlcNAc) [3].
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While the intriguing relationship between glycosyl-
ation and phosphorylation are still largely unex-
plored, evidence implicating monoglycosylation as a
potential regulatory mechanism continues to mount.
For instance, O-GlcNAc modi¢ed proteins are found
abundantly in the cytoplasm and nucleus [4]. The
modi¢cation is dynamic in response to a signaling
event [5]. Enzymes exist in the cytosol capable of
adding (uridine diphospho-N-acetylglucosamine:
polypeptide L-N-acetylglucosaminyltransferase) or re-
moving O-GlcNAc (N-acetyl-L-glucosaminidase
(O-GlcNAcase)) [6^8]. The O-GlcNAc transferase is
highly conserved among eukaryotes and contains
phosphorylated tyrosine suggesting that signaling
cascades may regulate O-GlcNAc transferase activity
[9,10]. Interestingly, several eukaryotic transcription
factors contain O-GlcNAc [11]. For example, re-
duced glycosylation of transcription factor Sp1 re-
sults in an increase in proteasome susceptibility
[12,13]. The transactivation domain of c-Myc is
O-glycosylated [14] and c-myc is known to induce
apoptosis in response to glucose [15]. Recently, the
murine estrogen receptor L has been found to be
both glycosylated and phosphorylated with these
modi¢cations apparently mutually exclusive [16]. Im-
portantly, phosphorylation of the transactivation do-
main leads to increased gene activation and rapid
receptor turnover, but the glycosylated form appears
to be less active and more stable [17]. With the grow-
ing number of transcription factors known to con-
tain O-GlcNAc, this modi¢cation appears to modu-
late many proteins that play important roles in cell
growth and proliferation. Therefore more informa-
tion is clearly needed to determine the function of
this modi¢cation and its e¡ects in both normal and
aberrant cell growth.
While little information is currently available on
O-GlcNAcase activity in mitogenic systems, the rel-
atively well characterized lysosomal L-hexosamini-
dase A and B isozymes have been examined in cer-
tain cancers. Studies on serum from cancer patients
[18], and tissue from colon [19], renal [20], breast
[21], and lung carcinomas [22] demonstrate a signi¢-
cant increase in lysosomal hexosaminidase activity.
We examined the more speci¢c O-GlcNAcase activ-
ity and monoglycosylation patterns in cancerous
breast tissue compared to adjacent normal breast
tissue in order to further our knowledge of the dy-
namic monoglycosylation system in a pathologically
proliferative environment.
2. Materials and methods
2.1. Chemicals and reagents
The chemicals used were all of the highest purity.
Primary antibodies were purchased from A⁄nity
Bioreagents (Boulder); secondary antibodies were
an anti-mouse horseradish peroxidase conjugate
from Bio-Rad (Hercules, CA). Wheat germ aggluti-
nin was purchased from E-Y Laboratories (San Ma-
teo, CA). Supersignal West Pico Chemiluminescent
Substrate was purchased from Pierce (Rockford, IL).
Radioisotopes were purchased from NEN (Boston,
MA). All other chemicals were obtained from Sigma
(St. Louis, MO).
2.2. Isolation of primary tissue
Human tissue was taken as part of lumpectomies,
mastectomies, or biopsies and was used with in-
formed consent of the patients. The size of the tissue
fragments was approx. 1 cm3. After removal from
the patient, the tissue was snap frozen in liquid nitro-
gen and stored at 370‡C. Tissue was judged to be
cancerous by a histological examination performed
by a pathologist, and adjacent breast tissue was sim-
ilarly determined to be normal.
2.3. Tissue homogenization
Frozen tissue was placed in liquid nitrogen and
ground into a ¢ne powder using a precooled mortar
and pestle. The frozen powder was stored for future
use at 370‡C. The powder was placed in a protease
inhibitor bu¡er (PIB) containing 25 mM Tris^Cl (pH
7.5), 1 mM sodium £uoride, 1 mM dithiothreitol,
20 Wg/ml leupeptin, 1 Wg/ml antipain, 15 Wg/ml benz-
amide, and 2 mM PMSF and sonicated on ice with
an Ultrasonic W-380 sonicator (6 s burst^30 s inter-
val^6 s burst^1 min interval^6 s burst at 40% duty
cycle, continuous pulse, and a microtip limit of 5).
The solution was clari¢ed by centrifugation at
5000Ug, and a soluble fraction was obtained by ul-
tracentrifugation of the supernatant at 110 000Ug
BBADIS 62053 6-9-01
C. Slawson et al. / Biochimica et Biophysica Acta 1537 (2001) 147^157148
[23]. The supernatant protein samples were collected
and assayed directly with a portion added to a pro-
tein solubilizing mixture (2.5% sodium dodecyl sul-
fate, 25% sucrose, 50 mM Tris pH 8.0, 5 mM EDTA,
1% pyronin Y, and 200 mM L-mercaptoethanol)
and stored at 320‡C for later analysis. Protein con-
centrations of the supernatant were determined by
the Bradford protein assay using immunoglobin G
(1 mg/ml) as a standard.
Fig. 1. Average hexosaminidase and O-GlcNAcase activity in matched tumor and adjacent tissue. (A) High speed supernatants were
assayed for hexosaminidase activity as described in Section 2. The assays were done in replicates of ¢ve, and the average for each
sample was used to calculate the mean. Total speci¢c activity of lysosomal hexosaminidases was then calculated from the mean activ-
ity of each sample. (B) Sets of identically treated samples were placed in MES bu¡er (pH 6.45) and assayed in the presence or absence
of the O-GlcNAcase inhibitor STZ. The total O-GlcNAcase activity (calculated as above) was increased in tumor compared to adja-
cent tissue. Average total activity was calculated as above. Error bars represent standard error.
BBADIS 62053 6-9-01
C. Slawson et al. / Biochimica et Biophysica Acta 1537 (2001) 147^157 149
2.4. Lysosomal hexosaminidase assay
Supernatant samples (10 Wl) were placed in 90 Wl
of 100 mM citrate-phosphate bu¡er (pH 5.3) con-
taining 2 mM p-nitrophenyl-GlcNAc. A set of ¢ve
replicates for each sample was incubated for 30 min
at 37‡C. The reactions were stopped by the addition
of 900 Wl of 0.5 M sodium carbonate (pH 12). The
absorbance of each solution was read at 400 nm and
compared to a control. The Beer^Lambert equation
was used to calculate speci¢c activity as nmoles/min/
mg of protein [24]. A mean activity was calculated
from the ¢ve replicates for each of the 12 samples.
These 12 means were summed. A mean and standard
error were calculated from this sum. We noticed a
loss of hexosaminidase activity over time and after
freeze thawing; therefore, all assays were performed
on freshly homogenized tissue.
2.5. O-GlcNAcase assay
O-GlcNAcase was assayed as described for hexos-
aminidase above with the following exceptions. A
0.2 M MES (pH 6.45) containing 2 mM p-nitrophen-
yl-GlcNAc was used in place of citrate-phosphate,
and a second set of identical samples were assayed
in the presence of the O-GlcNAcase inhibitor strep-
tozotocin (STZ) [25,26]. STZ was prepared in MES
bu¡er without p-nitrophenyl-GlcNAc at a con-
centration of 20 mM. Samples were diluted (50% v/
v) by the addition of the STZ solution (10 mM ¢nal
concentration), and incubated at 4‡C for 15 min.
STZ samples were treated as in the hexosaminidase
activity assay. The assay was stopped as before, and
speci¢c activity calculated using the Beer^Lambert
equation. The activity of the STZ sample was sub-
tracted from the non-treated sample and the di¡er-
ence comprised the apparent O-GlcNAcase activ-
ity.
2.6. Immunoblotting
Samples were separated on 10% SDS^PAGE
(1 mm thick minigels) then transferred at 12 V to
an Osmonics nitrobind nitrocellulose membrane us-
ing a Genie Electroblot system (5 mM Tris-base,
200 mM glycine, and 20% methanol) at 4‡C for 2 h.
The blot was allowed to dry overnight then incu-
bated at 70‡C in PBS (phosphate bu¡ered saline)
for 1 h [27,28]. The blot was blocked in high salt
PBST (HSPBST), 450 mM NaCl, 3 mM KCl,
5 mM Na2HPO4, 2 mM KH2PO4, and 0.02% Tween
20, containing 3% bovine serum albumin for 2 h.
Next, the blot was incubated in 1‡ antibody RL-2
(a monoclonal antibody speci¢c for a single
O-GlcNAc) at a dilution of 1/5000 in HSPBST, for
2 h at room temperature. RL-2 recognizes a subset of
O-GlcNAc bearing proteins and its binding is depen-
dent on the presence of the saccharide. After 5U10
min washes (50 ml each) in HSPBST, the gel was
incubated in anti-mouse coupled to horseradish per-
oxidase 2‡ antibody (1/40 000) in PBST. After 8U10
min washes (50 ml each) in PBST, the gel was incu-
bated in Pierce Supersignal for 5 min, exposed to ¢lm
as described by the manufacturer, and developed.
2.7. A⁄nity blotting
Samples were separated as before on SDS^PAGE
and transferred to a PVDF (polyvinyl di£uoride)
membrane. The blots were blocked in a TBST solu-
tion containing 5% BSA for 2 h at room temperature
and rinsed once with TBST before incubation in high
salt TBST (1 M NaCl) with WGA-HRP (1/10 000
dilution) [29] for 2 h at room temperature. They
were washed 3U10 min with HS-TBST and then
5U10 TBST (50 ml each) [24] prior to development
using DAB (diaminobenzidine 3 mM) and peroxide
(3%).
2.8. Isotopic labeling
Tissues were enzymatically labeled with radioac-
tive galactose [24]. A solution of 20 Wl containing
20^30 units/ml of L-galactosyltransferase, 25 mM
HEPES, 50 mM MnCl2, and 15 WCi of UDP-
[3H]galactose was added to cell homogenates (25 Wl)
and incubated at 37‡C for 1 h. The reaction was
stopped with the addition of 5 Wl of 10 mM EDTA
and 1% SDS. Proteins were precipitated by the addi-
tion of ice-cold ethanol at 15Ureaction volume for
18 h at 370‡C. The precipitated proteins were
pelleted by centrifugation at 10 000Ug and the super-
natant was removed. Proteins were dissolved in solu-
bilizing bu¡er (2.5% SDS, 25% sucrose, 25 mM Tris^
HCl pH 8.0, 2.5 mM EDTA, 210 mM L-mercapto-
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ethanol, and 5% pyronin Y) to a concentration of
2 Wg/Wl. Approx. 20 Wg of protein was loaded in
each lane for SDS^PAGE. Gels were brie£y stained
with Coomassie brilliant blue R (dissolved in 10%
methanol and 5% acetic acid) to con¢rm equivalency
of protein loaded. After destaining in 10% isopropa-
nol and 5% acetic acid, the gel was incubated in the
£uorographic solution EnHance (NEN) for 30 min.
The gel was transferred to a solution containing 2%
glycerol for 20 min and then vacuum dried. The
dried gel was placed with Kodak X-OMAT LS ¢lm
in a photographic cassette and exposed from 4 to
30 days at 370‡C. The ¢lm was developed in a Ko-
dak M35A X-OMAT processor.
Table 1
Hexosaminidase and O-GlcNAcase activity of each tumor and
adjacent tissue according to diagnosis and grade
(A) pH 5.3 hexosaminidase activity
Sample In¢ltrating ductal carcinoma
Total hexosaminidase Grade
T 3191 36.3 þ 0.04 2
A 3191 11.7 þ 0.38
T 1428a 13.4 þ 0.15 3
A 1428a 3.3 þ 0.09
T 2529 18.0 þ 0.03 3
A 2529 6.2 þ 0.03
T 1093 18.4 þ 0.15 3
A 1093 4.9 þ 0.03
T 2982 33.2 þ 0.58 3
A 2982 6.5 þ 0.06
T 0052 19.7 þ 0.03 3
A 0052 6.1 þ 0.02
T 2587 18.5 þ 0.06 3+
A 2587 3.9 þ 0.07
In¢ltrating and intraductal carcinoma
Total hexosaminidase Grade
T 4565 25.9 þ 0.24 2
A 4565 6.2 þ 0.14
T 3055 19.5 þ 0.06 3
A 3055 8.8 þ 0.06
Invasive ductal carcinoma
Total hexosaminidase Grade
T 1984 21.8 þ 0.60 3+
A 1984 5.5 þ 1.0
Adenocarcinoma
Total hexosaminidase Grade
T 0278 21.8 þ 0.05 3+
A 0278 6.3 þ 0.03
Lobular carcinoma
Total hexosaminidase Grade
T 3424 21.5 þ 0.03 2
A 3424 4.5 þ 0.02
Table 1 (continued)
(B) pH 6.45 O-GlcNAcase activity
Sample In¢ltrating ductal carcinoma
O-GlcNAcase Grade
T 3191 5.0 þ 0.08 2
A 3191 1.8 þ 0.38
T 1428a 3.0 þ 0.20 3
A 1428a 1.4 þ 0.13
T 2529 1.9 þ 0.05 3
A 2529 0.6 þ 0.04
T 1093 2.1 þ 0.07 3
A 1093 0.8 þ 0.15
T 2982 2.9 þ 0.23 3
A 2982 0.5 þ 0.02
T 0052 2.8 þ 0.03 3
A 0052 0.6 þ 0.04
T 2587 2.0 þ 0.06 3+
A 2587 0.4 þ 0.06
In¢ltrating and intraductal carcinoma
O-GlcNAcase Grade
T 4565 2.3 þ 0.18 2
A 4565 0.5 þ 0.15
T 3055 2.4 þ 0.10 3
A 3055 0.5 þ 0.06
Invasive ductal carcinoma
O-GlcNAcase Grade
T 1984 3.2 þ 0.30 3+
A 1984 2.3 þ 0.76
Adenocarcinoma
O-GlcNAcase Grade
T 0278 1.9 þ 0.08 3+
A 0278 0.6 þ 0.14
Lobular carcinoma
O-GlcNAcase Grade
T 3424 2.2 þ 0.06 2
A 3424 0.5 þ 0.03
(A) Acidic (pH 5.3) and (B) near neutral (pH 6.45) speci¢c ac-
tivity (nmoles/min/mg) of hexosaminidase and O-GlcNAcase for
individual tumor and adjacent samples with reported diagnosis
and tumor grade.
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3. Results
3.1. Hexosaminidase activity and O-GlcNAcase
activity
General hexosaminidase activity was examined us-
ing a standard pH 5.3 assay [24], while O-GlcNAcase
was measured at pH 6.45 using a subtractive ap-
proach. To measure the activity of O-GlcNAcase in
primary breast tumor and adjacent breast tissue
(matching set of 12 samples), we developed a mod-
i¢cation of the hexosaminidase assay taking advan-
tage of the more neutral pH optimum of O-Glc-
NAcase [8] and its sensitivity to the speci¢c
O-GlcNAcase inhibitor STZ [25,26]. O-GlcNAcase
is inhibited over 90% in the presence of STZ while
hexosaminidase activity is essentially una¡ected [25].
O-GlcNAcase activity was estimated by the di¡er-
ence from the total neutral hexosaminidase activity
and STZ inhibited activity. Using these two assays,
we observed increased levels of both the hexosamin-
idases and O-GlcNAcase in 12 sets of primary breast
tumor as compared to the matched adjacent breast
tissue (Fig. 1A,B). The values in the ¢gures represent
the summed means and standard error from the tu-
mor and adjacent tissue. Acidic hexosaminidase ac-
tivity (Table 1A) ranged from 13.4 to 36.3 nmoles/
min/mg in tumor tissue while in matched adjacent
tissue it ranged from 3.3 to 11.7, or approx. 25%
the activity of tumor tissue. The neutral assay yielded
values for O-GlcNAcase ranging from 2.0 to 5.0
nmoles/min/mg (Table 1B) in tumor tissue that
were also signi¢cantly higher than those in matched
adjacent tissue (0.4^2.3 nmoles/min/mg). Breast tu-
mor samples clearly show elevated levels of total
hexosaminidase and the more speci¢c O-GlcNAcase
compared to normal tissue (Fig. 1A,B). The di¡er-
ence is signi¢cant by analysis of variance (P6 0.05).
3.2. Evaluation of protein monoglycosylation
Since O-GlcNAcase is responsible for removing O-
GlcNAc from proteins and its activity was raised in
tumor tissue, we examined the levels of O-GlcNAc
monoglycosylated proteins in both tumor and adja-
cent breast tissue. As expected the monoglycosyla-
tion patterns found in the tumor and adjacent tissue
were complex. Several techniques, each with overlap-
ping speci¢city and di¡erent sensitivity, were used to
examine protein glycosylation. First, the RL-2 mono-
clonal antibody, a speci¢c probe for monoglycosyla-
tion of GlcNAc on serine/threonine residues, was
used to examine tissue via immunoblotting [26,30^
33]. Adjacent tissue (Fig. 2 left side and Fig. 3A)
shows multiple intensely labeled proteins in the
45^65 kDa area highlighted by one or more bands
near 55 kDa. Conversely the pattern is di¡erent in
tumor tissue where many tumors show elevated levels
of high molecular mass glycosylated proteins (s 90
kDa) but the monoglycosylation in the 45^65 kDa
range is decreased in seven of the eight samples
shown and 11 of 12 examined. Similarly, labeling
of a protein near 25^28 kDa is also consistently
more intense in adjacent breast tissue compared to
tumor tissue. Sample 3191 does not ¢t the pattern
and as will be seen with the [3H]galactose labeling
technique (see below) gives a consistent but unique
labeling pattern. As a control for antibody speci¢c-
ity, blots containing duplicate samples were cut in
half and probed with the RL-2 antibody with or
without competing N-acetylglucosamine monosac-
charide (Fig. 2) [26,30^33]. The side of the blot
treated with N-acetylglucosamine monosaccharide
Fig. 2. Immunoblot showing monoglycosylation patterns using
the RL-2 antibody speci¢c for serine/threonine linked N-acetyl-
glucosamine in the presence or absence of competing N-acetyl-
glucosamine. Samples were separated on SDS^PAGE, trans-
ferred to a nitrocellulose membrane that was cut in half, and
probed with the RL-2 antibody with or without 0.5 M N-ace-
tylglucosamine as described in Section 2. T refers to speci¢c tu-
mor tissue samples, and A refers to matched adjacent tissue
samples. Identical results were achieved in three separate experi-
ments. Molecular mass standards are shown on the left.
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shows almost complete loss of glycosylated bands
(Fig. 2); similar experiments with galactose showed
no change (data not shown). This competition
strongly indicates that the labeled proteins are modi-
¢ed by serine/threonine linked GlcNAc.
As a second method of examining the sugar mod-
i¢cations, the Western blots were probed with the
lectin wheat germ agglutinin (WGA) which has
been used in the past to examine O-GlcNAc mono-
glycosylation [24,29]. WGA binds terminal and clus-
tered N-acetylglucosamine residues and also sialic
acid [24]. An example of a WGA a⁄nity blot shows
a number of modi¢ed proteins (Fig. 3B), but the
same general pattern was seen. Namely, adjacent
breast tissue contains more intensely labeled bands
in the 45^65 kDa region that are reduced in tumor
tissue. Labeling of one or more bands near 65 kDa is
especially evident with this technique and most
prominent in adjacent tissue. Interestingly, samples
1428a and 1428b are tumors from the same patient
but from each breast. The banding patterns in the
samples are strikingly similar as would be expected
for normal tissue with the same genetic background.
This pattern further illustrates the consistency of the
a⁄nity labeling.
Finally, a sensitive enzymatic technique used pre-
viously to probe for monoglycosylated residues was
also employed [4,5,34]. This assay measures the
[3H]galactose transferred from UDP-[3H]galactose
to terminal N-acetylglucosamine residues by the en-
Fig. 4. Fluorographs of N-acetylglucosamine containing pro-
teins in tumor and adjacent tissue samples. (A,B) Glycosylation
patterns of sample tumor (T) and adjacent (A) tissue enzymati-
cally labeled with 3H-UDP-GlcNAc. Hen egg albumin, which
contains several terminal N-acetylglucosamine residues, was
used as a positive control. Individual tissue samples were ana-
lyzed (4^8 replicates each) with similar results. Molecular mass
standards are shown on the left.
Fig. 3. Immunoblot and a⁄nity blot probing monoglycosylation
of tumor and adjacent tissue. (A) Monoglycosylation patterns
of sample tumor (T) and adjacent (A) tissue using the RL-2
antibody. (B) The blot was a⁄nity probed with wheat germ ag-
glutinin; please notice from left to right lanes start with adja-
cent (A) followed by tumor (T) tissue. Similar results were
achieved in replicate experiments. Molecular mass standards are
shown on the left.
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zyme L-galactosyltransferase. The enzyme adds the
radioactive galactose moiety to any terminal GlcNAc
whether linked to another sugar, asparagine, or a
serine/threonine. Prior to labeling, samples were sub-
jected to a high-speed centrifugation in order to re-
move membrane and microsomal material as done
with the other assays. This minimizes contamination
from the typical asparagine linked or terminal extra-
cellular GlcNAc of traditional glycoproteins leaving
the soluble cytoplasmic and nuclear proteins to be
labeled [23]. The labeled proteins were separated by
SDS^PAGE and visualized by £uorography.
This sensitive enzymatic technique gave qualita-
tively similar results to the antibody and lectin
probes and also identi¢es a large number of labeled
proteins. Importantly, as before the amount of gly-
cosylation on speci¢c proteins was di¡erent in tumor
and adjacent tissue (Fig. 4A,B). For instance, while
labeling of at least 3^4 di¡erent bands in the 45^65
kDa range was visible in all adjacent tissue these
were greatly diminished or not present in 11/12
matched tumor samples. Labeling of low molecular
mass proteins (6 32 kDa) was less prominent in this
technique (see right hand arrows). Overall these sam-
ples showed protein labeling patterns qualitatively
similar to immuno- and a⁄nity blotting despite the
potential di¡erence in steric availability of O-
GlcNAc modi¢ed sites to the enzymatic labeling,
the antibody, or lectin recognition sites. Interestingly,
the antibody and the galactosyl transferase tech-
niques seem to identify proteins in the 50^55 kDa
range more strongly while the bands near 65 are
more strongly labeled by the lectin. In addition all
techniques show a larger number of labeled bands
with longer exposure times especially in the higher
molecular mass ranges (data not shown). This sug-
gests that samples contain an even larger number of
modi¢ed proteins present in lower concentrations
and/or that they interact less strongly with the label-
ing tools.
4. Discussion
In this study hexosaminidase and O-GlcNAcase
activities were measured in 12 matched primary
breast tumor and adjacent breast tissue samples.
The di¡erences in enzymatic activity between tumor
and adjacent breast tissue were signi¢cant as sup-
ported by analysis of variance. Increased activity in
both hexosaminidase and O-GlcNAcase in tumor tis-
sues corresponded with decreases in O-GlcNAc gly-
cosylation on proteins in the 45^65 kDa molecular
mass region on SDS^PAGE.
Earlier studies had shown elevated levels of lyso-
somal hexosaminidase activity in several di¡erent
malignant tumor tissues including colon [19], renal
[20], lung [22], and breast [21]. Our result con¢rms
the earlier study from breast tissue, but shows a
2-fold larger (3.5- versus 1.4-fold) increase in tumor
hexosaminidase activity. This small activity di¡er-
ence could be due to the type of tumor analyzed
and/or enzymatic stability. Our samples were com-
posed of 10 ductal carcinomas, one adenocarcinoma,
and one lobular carcinoma all with matched adjacent
tissue, while the previous study used a variety of
tumor tissue samples (ductal, lobular, medullary,
and adenocarcinomas). Other di¡erences in hexos-
aminidase activity could be due to storage and han-
dling of the homogenates. In our hands, the enzyme
activity was reduced during incubation at 4‡C (about
10% per hour, data not shown) and greatly reduced
by freeze thawing. In our study, enzyme activity was
measured as soon as possible upon tissue homogeni-
zation. Storage of the tissue at 370‡C did not de-
grade activity, and when samples of the same tissue
were homogenized at di¡erent times, the enzyme ac-
tivity was virtually identical (data not shown).
As well as elevated total hexosaminidase activity,
we also report for the ¢rst time the apparent activity
of an O-GlcNAcase in primary breast cancer tissue
and matched adjacent breast tissue. Interestingly, the
O-GlcNAcase activity like the total hexosaminidase
activity is also signi¢cantly higher in tumor tissue
compared to matched normal tissue, although at
present, we do not know if the activity is due to a
higher concentration of O-GlcNAcase or increased
activity of preexisting enzymes. Since O-GlcNAcase
can remove O-GlcNAc from serine or threonine [8],
the increased O-GlcNAcase activity suggests the po-
tential for a more rapid turnover of O-GlcNAc mod-
i¢cations in tumor tissue.
At least in some cases, the O-GlcNAc modi¢cation
is believed to be a reciprocal modi¢cation to protein
phosphorylation [3,35]. If this is true, rapidly prolif-
erating cells where increased protein phosphorylation
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is occurring should exhibit decreased speci¢c protein
monoglycosylation in at least a subset of proteins
that are reciprocally modi¢ed with phosphate or
GlcNAc. Okadaic acid, a phosphatase inhibitor,
has been shown to lead to a net increase in phos-
phorylation and decreases monoglycosylation in at
least one system, neuroblastoma cells [29]. The oka-
daic acid result is consistent with our ¢ndings in that
overall monoglycosylation has decreased in this pro-
liferative system (breast tumor). What is not known
in our system is the level of activity of the O-GlcNAc
transferase that adds the GlcNAc to speci¢c proteins.
O-GlcNAc transferase is a soluble protein that has
been shown to glycosylate transcription factors
(c-Myc) and certain kinases (casein kinase II) in vi-
tro, and is itself modi¢ed by O-GlcNAc and tyrosine
phosphorylation [9,36,37]. Unfortunately no com-
mercial antibody is available for the transferase,
and the enzymatic assay is di⁄cult because it re-
quires the synthesis of radioactive peptide substrates
and analysis via chromatography of the radioactive
products. The di⁄culty of the assay and the amount
of available tissue limited our study to only the
O-GlcNAcase.
It is not presently known how mitogenic signals
modulate the function of the O-GlcNAc transferase
nor how or if it is coordinated with the function of
the O-GlcNAcase. Interestingly, despite the mono-
glycosylation decrease in the 45^65 kDa range, tu-
mor tissue did show an increase in glycosylation of
several higher molecular mass proteins (s 90 kDa).
Glycosylation of these higher molecular mass pro-
teins might be due to any one or a combination of
causes. These include changes in speci¢city of the
transferase or O-GlcNAcase, more abundant expres-
sion of the modi¢ed proteins, or a signal transduc-
tion mediated conformational change that renders
these higher molecular mass proteins more suscepti-
ble to glycosylation and/or less susceptible to degly-
cosylation.
In contrast to tumor tissue, the normal adjacent
tissue demonstrated an intensely glycosylated region
representing proteins between 45 and 65 kDa. The
region is composed of at least four glycosylated pro-
teins, and the amount of glycosylation of this region
is clearly diminished in tumor tissue. Although the
identities of these proteins are at present not known,
several known O-GlcNAc containing proteins do ¢t
within this molecular mass range. The p62 nuclear
pore complex contains four glycosylated proteins,
p45, p54, p58, and p62 [38^41]. The glycosylated
nuclear pore complex is critical for signal sequence
recognition and active protein transport across the
nuclear membrane [42]. Other potential candidates
are transcription factors or several of the cytokera-
tins. The transcription factor p53 is an O-GlcNAc
containing protein that binds DNA more e¡ectively
when glycosylated in EB-1 cells [43]. Conversely, the
murine estrogen receptor L transactivation domain,
which is reciprocally modi¢ed by glycosylation or
phosphorylation on serine-16, is more transcription-
ally active when phosphorylated but more stable
when glycosylated [17]. Additionally, several cytoker-
atin proteins (cytokeratins 8 and 18) are glycosylated
and are in this molecular mass range [44]. Cytoker-
atins are abundant in epithelial tissue from which
these tumors are derived and undergo several post-
translational modi¢cations, such as O-glycosylation
[44]. Identi¢cation and characterization of the pro-
teins highlighted in this study will be an important
step in elucidating their relationship to cancer.
In conclusion, acidic L-hexosaminidase and
O-GlcNAcase activity are signi¢cantly increased in
primary breast tumors compared to normal adjacent
tissue. While this study shows multiple O-GlcNAc
modi¢ed proteins in tumor tissue, adjacent tissue
contains at least four glycosylated proteins in the
molecular mass region of 45^65 kDa that are degly-
cosylated in tumor tissue. The net loss of O-GlcNAc
modi¢cations in tumor tissue is correlated with the
increase in O-GlcNAcase activity. While the O-
GlcNAcase activity was consistently elevated in the
tumor tissue there was no simple correlation between
O-GlcNAcase activity and tumor grade or diagnosis
in this group of 12 breast tissue samples. Clearly
studies with a larger number of well-characterized
tumor samples would allow more complete analysis
of the association of O-GlcNAcase activity with clin-
ically relevant identi¢ers of prognosis and treatment.
Since tumor tissue shows both elevated levels of
O-GlcNAcase and altered monoglycosylation pro-
¢les, a better understanding of the role of these
changes in the transformation process and progres-
sion of the cancerous state will be necessary to take
full advantage of this information in the clinical set-
ting.
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